克林澳早期治疗中重型颅脑损伤的临床观察

Clinical study on cinepazide maleate for acute moderate and severe brain injury

目的:探讨早期应用克林澳对急性中重型颅脑损伤患者的治疗作用。方法:将76例急性颅脑损伤患者随机分为治疗组和对照组,每组38例。患者药物治疗均在颅脑损伤后6小时内,对照组给予常规治疗,治疗组在对照组的基础上加用克林澳静脉滴注160mg/d,连续14天为1个疗程。把意识觉醒时间、GCS评分、TCD以及GOS评分作为观察指标。结果:两组对比,治疗组意识觉醒时间,不同时期GCS评分,经TCD显示缓解脑血管痉挛效果以及预后GOS评分均优于对照组,差异有统计学意义,无明显不良反应。结论:早期应用克林澳治疗急性中重型颅脑损伤,疗效可靠,可降低致残率。

Objective：To explore the therapeutic effects of Cinepazide Maleate （CM） for acute moderate and severe brain injury, Methods：The 76 patients with acute brain injury were divided randomly into two groups including CM group and control group, with 38 cases in each group.All the patients were treated in six hours after injury, Both groups received the standard therapy, meanwhile 38 cases in CM group were administrated with 160 mg/d CM for two weeks. According to awakening time, GCS score, TCD and GOS evaluation, the different prognosis between two groups was analysed. Results：There was a significant difference on awakening time between the CM group and the Control group in the patients with acute moderate and severe brain injury ;There was a significant difference on GCS score between two groups;The CVS was obviously improved in CM group than that in control group by TCD examination ;The prognosis of the CM group was better than that of the control group. Conclusion：The therapeutic effects can be improved, and the rates of death and disability can be decreased by the administration of CM in patients with acute moderate and severe brain injury.